Newsroom

May 8, 2025

RiskScore Study Published in JCO Precision Oncology

Read more
April 25, 2025

Can Humans and Robots Speak the Same Language? Engineering the Labs of Tomorrow

Read more
April 14, 2025

'Happy, healthy and focused' | DNA testing in Mason helps patients find mental health medications faster

Read more
April 1, 2025

Patients Like Olivia Munn and Florence Pugh Are Devoted to Her. Meet Famed OB-GYN, Dr. Thaïs Aliabadi

Read more
March 17, 2025

The outsized impact of employee benefits on HR’s value to an org

Read more
February 12, 2025

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

Read more
February 9, 2025

Hannah Storm's breast cancer diagnosis was a shock. Now the veteran sports journalist is helping others understand their risk

Read more
February 6, 2025

Hannah Storm breaks down latest with NBA trade deadline, Luka Doncic and more

Read more
February 3, 2025

Dallas Reed, MD, highlights trends and barriers in prenatal genetic testing

Read more
previous slide
    next slide

    Scientific publications

    See all

    Key study finding: ctDNA levels detected using Precise MRD were associated with patients’ response to metastasis-directed radiation therapy

    DOI: 10.1016/S1470-2045(25)00380-8
    Publication Press release

    Meta-Analysis demonstrates that Access to the GeneSight test can significantly improve response and remission rates for patients with depression

    DOI: 10.1097/JCP.0000000000002061
    Publication Press release

    Study suggest that utilizing RiskScore drives breast cancer screening tailored to individual risk

    DOI: 10.1200/PO-24-00716
    Publication Press release

    Study results show patients with depression had fewer psychiatric hospitalizations after GeneSight testing

    DOI: 10.1097/JCP.0000000000001999
    Publication Press release

    Prolaris can predict the benefit of hormone therapy treatment in localized prostate cancer

    DOI: 10.1200/PO.23.00722
    Publication Press release
    previous slide
      next slide

      Press releases

      See all

      Mar 17, 2026

      Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer 

      Read more

      Mar 02, 2026

      Myriad Commercially Launches Precise MRD with Select Community Oncologists

      Read more

      Feb 24, 2026

      Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

      Read more

      Feb 23, 2026

      Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

      Read more

      Public relations contacts

      Kate Schraml

      pr@myriad.com

      Investor relations contacts

      Matt Scalo

      ir@myriad.com
      X social media icon Linkedin social media icon

      About Myriad Genetics

      Myriad Genetics is a leader in genetic testing and precision medicine, providing insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease. 

      • Early insights helped Ashley prepare

        “Carrier screening empowers you to make the right decisions. Not only are you making a decision for yourself right now but you’re making a decision for the next 80, 90, 100 years to create a better life for you and your baby.”
        Watch Ashley's story

      • Prenatal screening gave Hannah time to plan

        “Once we got the noninvasive prenatal screening results back, we were able to meet with a lot more physicians.”

      • How Prolaris provided clarity for his prostate cancer treatment plan

        “Prolaris gave me the ability to maintain the lifestyle that my wife and I have lived with for many years now.”
        Watch Tim's story
      previous slide
        next slide